1. JDRF Advocacy: Turning Type One Into Type None JESSICA ROTH Senior Director, Health Policy, JDRF

2. JDRF Advocacy: Advancing Life- Changing Therapies
Jessica Roth
Senior Director, Health Policy
JDRF Advocacy

3. Both Research and Advocacy Critical to Driving Progress through the Pipeline

4. As JDRF Evolves, Role of Advocacy Growing
We WERE the Juvenile Diabetes Research Foundation
Now We ARE JDRF
Singularly focused on a cure and identified only with children
Expanding reach to include adults and therapies that cure, treat and prevent T1D for all ages at all stages
Focused simply on funding research
Seeking to dramatically increase research we fund while influencing government, industry, and others to invest in T1D
Focused mostly on basic research in an academic setting
Increasing emphasis on translational research and removing obstacles at FDA and elsewhere to enable new, innovative therapies delivered to people with T1D

5. Advocacy Raises Public Funds for R&D
Funding for R&D in JDRF Priority Areas

6. Special Diabetes Program T1D Funding 1998–2015
JDRF Helped Secure More Than $2 Billion in Special Diabetes Program Funds Alone
Special Diabetes Program T1D Funding 1998–2015

7. JDRF Engages NIH to Ensure SDP Research Funds Used for JDRF Priority Areas (FY13)
Kidney Trial
$24.3 M
Other
Causes
Complications
Management
Cell

8. Advocacy Helps Advance Regulatory Pathways

9. JDRF Advocacy Has Reduced Regulatory Barriers for Artificial Pancreas
Result:
More Reasonable Pathway for R&D Progress

10. Advocacy Helped Advance Health Reimbursement
Health Plan Coverage & Adoption

11. JDRF CGM Campaign Achieved Health Plan Coverage and Clinical Guidelines

12. JDRF Developing Heath Policy Strategies for All Priority T1D Therapies
Smart Insulin
Encapsulation
Artificial Pancreas
Prevention
Restoration
Complications

13. Health Policy Strategic Planning Underway
To ensure patient access to life-changing T1D therapies
JDRF Goal:
There are three central challenges to obtaining this goal:
Therapies must be accessible and affordable for people with T1D
Therapies must be attractive enough to companies that they will invest in product development
Therapies must meet insurers’ increasingly high demands for clinical evidence, as well as justification for cost of therapy

14. Current Advocacy Issues
Special Diabetes Program (SDP) Renewal
Secure at least a one-year renewal of the SDP before the program expires this September
Medicare Coverage of CGMs
Build support in Congress for the Medicare CGM Access Act
Appropriations for NIH & FDA
Advocate for strong annual funding for each agency to advance T1D research and therapies
Note: SDP is not appropriations

15. JDRF 2015 Children’s Congress

16. Promise to Remember Me Campaign

17. How You Can Help! Sign up to be a JDRF advocate!
Go to or
Text Action to (JDRF1)
Respond to action alerts and join in meetings with Members of Congress
Encourage friends, family, co-workers and others to become advocates.